Author:
Kitai Yuki,Watanabe Oshi,Ohmiya Suguru,Kisu Tomoko,Ota Reiko,Kawakami Kazuyoshi,Katoh Hiroshi,Fukuzawa Kaori,Takeda Makoto,Nishimura Hidekazu
Abstract
AbstractOur previous findings indicated that many respiratory syncytial virus (RSV) isolates are unstable at 4 °C compared to 20 °C. Some of the strains completely lose infectivity after 24 h at 4 °C. This study analyzed the inactivation process at 4 °C using a representative strain, RSV/Sendai/851/13. After 24 h of storage at 4 °C, the virus was completely inactivated but retained its ability to attach to and to be taken into host cells. It suggested a reduced fusion ability between the viral and cellular membranes. During storage at 4 °C, the RSV fusion (F) protein underwent a conformational change and was no longer recognized by pre-fusion form-specific antibodies. When the RSV/Sendai/851/13 strain was passaged at 4 °C, a variant with an amino acid substitution, I148T, in the F protein fusion peptide was selected. Also, an amino acid change in G protein demonstrating stability at low temperatures was obtained. These results show that the inactivation of RSV at 4 °C is due to the loss of membrane fusion activity in the F protein, which cannot maintain its pre-fusion state at 4 °C.
Funder
Japan Society for the Promotion of Science
Japan Agency for Medical Research and Development
Shionogi Infectious Disease Research Promotion Foundation
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Ebbert, J. O. & Limper, A. H. Respiratory syncytial virus pneumonitis in immunocompromised adults: Clinical features and outcome. Respiration 72, 263–269. https://doi.org/10.1159/000085367 (2005).
2. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial virus infection in elderly and high-risk adults. Engl. J. Med. 352, 1749–1759 (2005).
3. Resch, B. Burden of respiratory syncytial virus infection in young children. World J. Clin. Pediatr. 1, 8–8. https://doi.org/10.5409/wjcp.v1.i3.8 (2012).
4. Fda & Cber. May 23, 2023 Approval Letter-AREXVY. (2023).
5. Fda & Cber. May 31, 2023 Approval Letter-ABRYSVO. (2023).